TG Therapeutics/$TGTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Ticker
- $TGTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 399
- Headquarters
- Morrisville, United States
- Website
- www.tgtherapeutics.com
TG Therapeutics Metrics
BasicAdvanced
$8.7B
22.10
$2.77
1.66
-
Price and volume
Market cap
$8.7B
Beta
1.66
52-week high
$61.76
52-week low
$26.76
Average daily volume
1.6M
Financial strength
Current ratio
4.267
Quick ratio
3.552
Long term debt to equity
1.246
Total debt to equity
1.249
Interest coverage (TTM)
3.64%
Profitability
EBITDA (TTM)
136.451
Gross margin (TTM)
82.37%
Net profit margin (TTM)
55.22%
Operating margin (TTM)
17.05%
Effective tax rate (TTM)
-334.54%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
7.28%
Return on equity (TTM)
100.28%
Valuation
Price to earnings (TTM)
22.096
Price to revenue (TTM)
10.905
Price to book
14.87
Price to tangible book (TTM)
14.37
Price to free cash flow (TTM)
501.517
Free cash flow yield (TTM)
0.20%
Free cash flow per share (TTM)
0.122
Growth
Revenue change (TTM)
76.08%
Earnings per share change (TTM)
667.52%
3-year revenue growth (CAGR)
221.54%
10-year revenue growth (CAGR)
135.50%
3-year earnings per share growth (CAGR)
29.65%
10-year earnings per share growth (CAGR)
8.20%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
Analyst projections of the future price of TG Therapeutics stock.
Bulls say / Bears say
BRIUMVI’s commercial momentum is strong: US sales grew 64% year on year to $227.7 million in Q2, and TG Therapeutics raised its 2026 global revenue target to about $950 million. Further guidance upgrades would support the case that the launch still has room to grow. (TG Therapeutics)
A Phase 3 trial found that patients could start BRIUMVI with one infusion instead of two, meeting its bioequivalence goal. If adopted, the simpler start could reduce treatment burden and make it easier for patients to switch to BRIUMVI. (TG Therapeutics)
A quarterly subcutaneous version could let BRIUMVI compete for patients who prefer an injection to an infusion. Phase 1 results supported the planned dosing approach, and the pivotal Phase 3 study was fully enrolled, although the commercial opportunity still depends on a successful trial and approval. (TG Therapeutics)
Revenue is heavily concentrated in BRIUMVI: US sales of $227.7 million accounted for most of the company’s $240.3 million Q2 revenue. A setback in demand, reimbursement or supply could therefore have a large effect on results. (TG Therapeutics, SEC)
Higher spending is eating into the benefit of rapid sales growth: Q2 net income fell to $7.8 million from $28.2 million a year earlier, while research and development and selling costs rose. The company also expects about $100 million of 2026 costs tied to subcutaneous manufacturing and starting a second supplier. (TG Therapeutics)
BRIUMVI faces established rivals in the anti-CD20 market, including Roche’s Ocrevus. Industry reporting says substantial discounts may be needed to persuade payers to switch, which could constrain BRIUMVI’s pricing and margins even if prescriptions grow. (Investing.com, Citeline)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
TG Therapeutics News
AllArticlesVideos
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
Business Wire3 weeks ago
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
Business Wire3 weeks ago
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
MarketBeat1 month ago
Funds containing TG Therapeutics
AllUSDEURGBP
Fund name | Fund size | $TGTX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.77% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.77% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.77% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.46% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.46% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.